Mitochondrial DNA Copy Number Variations and Serum Pepsinogen Levels for Risk Assessment in Gastric Cancer

Mehdi Alikhani (1) , Samaneh Saberi (1) , Maryam Esmaeili (1) , Valérie Michel (2) , Mohammad Tashakoripour (3) , Afshin Abdirad (3) , Arezoo Aghakhani (1) , Sana Eybpoosh (1) , Massoud Vosough (4) , Mohammad Ali Mohagheghi (3) , Mahmoud Eshagh Hosseini (3) , Eliette Touati (2) , Marjan Mohammadi (1)

1 Institut Pasteur d'Iran
2 Pathogenèse de Helicobacter / Helicobacter Pathogenesis
3 TUMS - Tehran University of Medical Sciences
4 ACECR - Academic Center for Education, Culture and Research

Background: Variations in mtDNA-CN of PBLs, as a potential biomarker for GC screening has currently been subject to controversy. Herein, we have assessed its efficiency in GC screening, in parallel and in combination with sPG I/II ratio, as an established indicator of gastric atrophy. Methods: The study population included GC (n = 53) and non-GC (n = 207) dyspeptic patients. The non-GC group was histologically categorized into CG (n = 104) and NM (n = 103) subgroups. The MtDNA-CN of PBLs was measured by quantitative real-time PCR. The sPG I and II levels and anti-H. pylori serum IgG were measured by ELISA. Results: The mtDNA-CN was found significantly higher in GC vs. non-GC (OR = 3.0; 95% CI = 1.4, 6.4) subjects. Conversely, GC patients had significantly lower sPG I/II ratio than the non-GC (OR = 3.2; CI = 1.4, 7.2) subjects. The combination of these two biomarkers yielded a dramatic amplification of the odds of GC risk in double-positive (high mtDNA-CN-low sPGI/II) subjects, in reference to double-negatives (low mtDNA-CN-high sPGI/II), when assessed against non-GC (OR = 27.1; CI = 5.0, 147.3), CG (OR = 13.1; CI = 2.4, 72.6), or NM (OR = 49.5; CI = 7.9, 311.6) groups. Conclusion: The combination of these two biomarkers, namely mtDNA-CN in PBLs and serum PG I/II ratio, drastically enhanced the efficiency of GC risk assessment, which calls for further validations.

Mots clés: gastric cancer; Helicobacter pylori; mitochondrial DNA copy number; serum pepsinogen; Biomarkers; DNA copy number variation; Mitochondrial DNA; Stomach neoplasms

Domaines: Cancer

Mehdi Alikhani, Samaneh Saberi, Maryam Esmaeili, Valérie Michel, Mohammad Tashakoripour, et al.. Mitochondrial DNA Copy Number Variations and Serum Pepsinogen Levels for Risk Assessment in Gastric Cancer. Iranian Biomedical Journal, 2021, 25 (5), pp.323-33. ⟨10.52547/ibj.25.5.323⟩. ⟨pasteur-03688632⟩